Literature DB >> 19817984

Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function.

R W Hunter1, I Hers.   

Abstract

OBJECTIVES: As platelets express both insulin and insulin-like growth factor-1 (IGF-1) receptors, their subunits may randomly heterodimerize to form insulin/IGF-1 receptor hybrids, which avidly bind IGF-1, but not insulin. This study investigated the possibility that platelets express hybrid receptors, which may affect insulin action on platelet function.
METHODS: Platelets were incubated with insulin and IGF-1. Expression and phosphorylation of insulin/IGF-1 receptors was determined by western blotting of immunoprecipitates, and compared with platelet functional responses. Relative expression of insulin and IGF-1 receptors was estimated by competitive ligand binding and quantitative polymerase chain reaction.
RESULTS: We demonstrated the presence of insulin/IGF-1 hybrid receptors on human platelets by detecting both insulin and IGF-1 receptor beta subunits in coimmunoprecipitation studies. Stimulation of platelets with insulin (1-100 nm) resulted in tyrosine phosphorylation of insulin receptors, but not of hybrid receptors. High insulin concentrations (50-100 nm) stimulated weak phosphorylation of IGF-1 receptors and protein kinase B (Akt), and correlated with moderately increased aggregation and fibrinogen binding, whereas low insulin concentrations (1-10 nm) had no effect. In contrast, IGF-1 (1-100 nm) induced strong phosphorylation of both hybrid and IGF-1 receptors, and potentiated platelet aggregation and fibrinogen binding. Specific binding of [(125)I]IGF-1 (1.08% +/- 0.16%) was significantly higher than that of [(125)I]insulin (0.15% +/- 0.03%). Accordingly, IGF-1 receptor mRNA was more abundant than insulin receptor mRNA (IGF-1 receptor/insulin receptor ratio 69 +/- 3.8).
CONCLUSIONS: Insulin has minimal effects on platelet function, which can be explained by the relatively low insulin receptor expression levels resulting in the majority of insulin receptor subunits being expressed as insulin/IGF-1 hybrids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817984     DOI: 10.1111/j.1538-7836.2009.03637.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

Review 1.  Platelet-rich plasma and the elimination of neuropathic pain.

Authors:  Damien P Kuffler
Journal:  Mol Neurobiol       Date:  2013-07-07       Impact factor: 5.590

2.  Akt signaling in platelets and thrombosis.

Authors:  Donna S Woulfe
Journal:  Expert Rev Hematol       Date:  2010-02       Impact factor: 2.929

Review 3.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 4.  Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.

Authors:  S Farhan; I Tentzeris; M K Freynhofer; B Vogel; K Huber
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

Review 5.  The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium.

Authors:  V Kate Gatenby; Helen Imrie; Mark Kearney
Journal:  Pflugers Arch       Date:  2013-01-22       Impact factor: 3.657

Review 6.  Platelet function profiles in patients with diabetes mellitus.

Authors:  Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-02-13       Impact factor: 4.132

7.  In-depth PtdIns(3,4,5)P3 signalosome analysis identifies DAPP1 as a negative regulator of GPVI-driven platelet function.

Authors:  Tom N Durrant; James L Hutchinson; Kate J Heesom; Karen E Anderson; Len R Stephens; Phillip T Hawkins; Aaron J Marshall; Samantha F Moore; Ingeborg Hers
Journal:  Blood Adv       Date:  2017-06-13

Review 8.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

9.  Antithrombotic therapy in diabetes: which, when, and for how long?

Authors:  Ramzi A Ajjan; Noppadol Kietsiriroje; Lina Badimon; Gemma Vilahur; Diana A Gorog; Dominick J Angiolillo; David A Russell; Bianca Rocca; Robert F Storey
Journal:  Eur Heart J       Date:  2021-06-14       Impact factor: 29.983

10.  Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes.

Authors:  Galia Spectre; Claes-Göran Östenson; Nailin Li; Paul Hjemdahl
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.